Huntington's Disease (HD)


Huntington's disease (HD) is a neurodegenerative genetic disorder that affects muscle coordination and leads to cognitive decline and behavioural symptoms.

Cannabis Medical Journals

2013 - Study ~ Cannabinoids increase type 1 cannabinoid receptor expression in a cell culture model of striatal neurons: implications for Huntington's disease.

2013 - Study ~ In vitro and in vivo models of Huntington's disease show alterations in the endocannabinoid system.

2013 - Study ~ CNR1 variation is associated with the age at onset in Huntington disease.

2013 - Study ~ Therapeutic Potential of Cannabinoids in Neurodegenerative Disorders: A Selective Review.

2013 - Study ~ The Influence of Cannabinoids on Generic Traits of Neurodegeneration.

2012 - Study ~ Cannabinoids: Novel Medicines for the Treatment of Huntington's Disease.

2012 - Study ~ Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid?

2012 - Study ~ Cannabinoid modulation of neuroinflammatory disorders

2012 - Study ~ The dynamic nature of type 1 cannabinoid receptor (CB1) gene transcription

2012 - Study ~ The endocannabinoid system in normal and pathological brain ageing

2012 - Study ~ Sativex-like Combination of Phytocannabinoids is Neuroprotective in Malonate-Lesioned Rats, an Inflammatory Model of Huntington's Disease: Role of CB(1) and CB(2) Receptors.

2012 - Study ~ Downregulation of cannabinoid receptor 1 from neuropeptide Y interneurons in the basal ganglia of patients with Huntington's disease and mouse models.

2012 - Study ~ Cannabinoid Receptor 2 Signaling in Peripheral Immune Cells Modulates Disease Onset and Severity in Mouse Models of Huntington's Disease.

2011 - Study ~ Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease.

2011 - Study ~ Prospects for cannabinoid therapies in basal ganglia disorders.

2011 - Study ~ Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease.

2011 - Study ~ Worsening of Huntington disease phenotype in CB1 receptor knockout mice.

2011 - Study ~ Metabolic and Type 1 cannabinoid receptor imaging of a transgenic rat model in the early phase of Huntington disease.

2010 - Study ~ Widespread Decrease of Type 1 Cannabinoid Receptor Availability in Huntington Disease In Vivo.

2010 - Study ~ Cannabinoids and Dementia: A Review of Clinical and Preclinical Data.

2010 - Study ~ Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: a neuroprotective therapeutic modality.

2010 - Study ~ Neuroprotective potential of CB1 receptor agonists in an in vitro model of Huntington's disease.

2009 - Study - The endocannabinoid system as a target for the treatment of motor dysfunction.

2009 - Study ~ Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity.

2009 - Study ~ Altered CB1 receptor and endocannabinoid levels precede motor symptom onset in a transgenic mouse model of Huntington's disease.

2009 - Study ~ The endocannabinoid system as a target for the treatment of motor dysfunction.

2009 - Study ~ A pilot study using nabilone for symptomatic treatment in Huntington's disease.

2009 - Study ~ Cannabinoids and neurodegenerative diseases.

2009 - Study ~ Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease.

2008 - Study ~ Altered Lipid Metabolism in Brain Injury and Disorders.

2008 - Study ~ The endocannabinoid system in Huntington's disease.

2008 - Study ~ The endocannabinoid pathway in Huntington's disease: a comparison with other neurodegenerative diseases.

2007 - Study ~ Cannabinoids and neuroprotection in motor-related disorders.

2006 - Study ~ UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders.

2006 - Letter - Nabilone Could Treat Chorea and Irritability in Huntington's Disease.

2005 - Study ~ Cannabinoid control of motor function at the basal ganglia.

2005 - Study ~ Abnormal sensitivity to cannabinoid receptor stimulation might contribute to altered gamma-aminobutyric acid transmission in the striatum of R6/2 Huntington's disease mice.

2004 - Study ~ Structure, expression and regulation of the cannabinoid receptor gene (CB1) in Huntington's disease transgenic mice.

2004 - Study ~ Delayed onset of Huntington's disease in mice in an enriched environment correlates with delayed loss of cannabinoid CB1 receptors.

2003 - Study ~ Compounds acting at the endocannabinoid and/or endovanilloid systems reduce hyperkinesia in a rat model of Huntington's disease.

2003 - Study ~ Effects of cannabinoids in the rat model of Huntington's disease generated by an intrastriatal injection of malonate.

2003 - Study ~ The endocannabinoid system and Huntington's disease.

2002 - Study ~ Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease.

2002 - Study ~ Loss of cannabinoid CB(1) receptors in the basal ganglia in the late akinetic phase of rats with experimental Huntington's disease.

2001 - Study ~ Changes in endocannabinoid transmission in the basal ganglia in a rat model of Huntington's disease.

2000 - Study ~ Cannabinoid Receptor Messenger Rna Levels Decrease in a Subset of Neurons of the Lateral Striatum, Cortex and Hippocampus of Transgenic Huntington's Disease Mice.

1999 - Study ~ Cannabis in movement disorders.

1993 - Study ~ Loss of cannabinoid receptors in the substantia nigra in Huntington's disease.

1986 - Study - Effects of Cannabidiol in Huntington Didease.

1981 - Study ~ Tetrahydrocannabinol potentiates reserpine-induced hypokinesia.